Enomoto T, Okada H, Tomita H, et al. Glycocalyx analysis of bladder cancer: three-dimensional images in electron microscopy and Vicia villosa lectin as a marker for invasiveness in frozen sections. Front Cell Dev Biol. 2023;11:1308879.

PubMed  Google Scholar 

Tak S, Han G, Leem S-H, et al. Prediction of anticancer drug resistance using a 3d microfluidic bladder cancer model combined with convolutional neural network-based image analysis. Front Bioeng Biotechnol. 2023;11:1302983.

PubMed  Google Scholar 

Jing S, Yang E, Luo Z, et al. Perioperative outcomes and continence following robotic-assisted radical cystectomy with Mainz pouch II urinary diversion in patients with bladder cancer. BMC Cancer. 2024;24(1):127.

CAS  PubMed  PubMed Central  Google Scholar 

Ma YY, Zhang GJ, Liu PF, et al. Comprehensive genomic analysis of puerarin in inhibiting bladder urothelial carcinoma cell proliferation and migration. Recent Pat Anticancer Drug Discov. 2023;19(4):516–29.

PubMed Central  Google Scholar 

Kurabayashi A, Fukuhara H, Furihata K, et al. Photodynamic diagnosis and therapy in non-muscle-invasive bladder cancer. Cancers (Basel). 2024;16(13):2299.

CAS  PubMed  PubMed Central  Google Scholar 

Savin Z, Mano R, Lazarovich A, et al. Assessing the impact of percutaneous nephrostomy presence on neoadjuvant treatment quality in patients with muscle invasive bladder cancer. Clin Genitourin Cancer. 2024;22(2):491–6.

PubMed  Google Scholar 

Abou Chakra M, Packiam VT, Duquesne I, et al. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Expert Opin Pharmacother. 2024;25(2):203–14.

CAS  PubMed  Google Scholar 

Paliogiannis P, Lobrano R, Bella MA, et al. Pd-L1 Immunohistochemical expression in bladder urothelial cancer with Sp263, Sp142 and 22c3 antibodies: a comparative study. Ann Diagn Pathol. 2024;69: 152267.

PubMed  Google Scholar 

Alcantara MB, Tang WS, Wang D, et al. Targeting Stat3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. Front Immunol. 2023;14:1274781.

CAS  PubMed  Google Scholar 

Gong Y, Cheng Y, Zhang J, et al. Role of additional MRI-based morphologic measurements on the performance of VI-RADS for muscle-invasive bladder cancer. J Magn Reson Imaging. 2024;60:1113–23.

PubMed  Google Scholar 

Huang S, Huang Y, Li C, et al. Efficacy and safety of neoadjuvant Pd-1 inhibitors or Pd-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1332213.

CAS  PubMed  Google Scholar 

Kochergin M, Fahmy O, Asimakopoulos A, et al. Photodynamic therapy: current trends and potential future role in the treatment of bladder cancer. Int J Mol Sci. 2024;25(2):960.

CAS  PubMed  PubMed Central  Google Scholar 

Ghannam SF, Makhlouf S, Alsaleem M, et al. The conflicting prognostic role of the stroma-ratio in breast cancer molecular subtypes. Mod Pathol. 2024;29: 100607. https://doi.org/10.1016/j.modpat.2024.100607.

Article  CAS  Google Scholar 

Li Y, Ma J, Ma X, et al. PD-L1 expression and tumor-infiltrating lymphocytes: correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping. Pathol Res Pract. 2024;23(262): 155556. https://doi.org/10.1016/j.prp.2024.155556.

Article  CAS  Google Scholar 

Li Y, Yang K, Li K, et al. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. J Cell Biochem. 2019;120(6):9956–63. https://doi.org/10.1002/jcb.28278.

Article  CAS  PubMed  Google Scholar 

Liu S, Zhai J, Li D, et al. Identification and validation of molecular subtypes’ characteristics in bladder urothelial carcinoma based on autophagy-dependent ferroptosis. Heliyon. 2023;9(11): e21092. https://doi.org/10.1016/j.heliyon.2023.e21092.

Article  PubMed  PubMed Central  Google Scholar 

Guo CC, Bondaruk J, Yao H, et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep. 2020;10(1):9743. https://doi.org/10.1038/s41598-020-66747-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garczyk S, Bischoff F, Schneider U, et al. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer. Virchows Arch. 2021;479(2):325–35. https://doi.org/10.1007/s00428-021-03054-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rasti A, Khalili M, Fakhr Yasseri AM, et al. Evaluation of IGF2, KRT14, and KRT20 as urinary biomarkers in patients with bladder cancer. Rep Biochem Mol Biol. 2023;11(4):710–9. https://doi.org/10.52547/rbmb.11.4.710.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81(5):523–32. https://doi.org/10.1016/j.eururo.2021.10.035.

Article  CAS  PubMed  Google Scholar 

Kaczmarek K, Plage H, Furlano K, et al. Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder. Int Urol Nephrol. 2024;56(2):499–508. https://doi.org/10.1007/s11255-023-03800-0.

Article  CAS  PubMed  Google Scholar 

Zhu X, Chan E, Turski ML, et al. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024;29(8):e1094–7. https://doi.org/10.1093/oncolo/oyae127.

Article  PubMed  PubMed Central  Google Scholar 

Shi MJ, Fontugne J, Moreno-Vega A, et al. FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias. Eur Urol. 2023;83(1):70–81. https://doi.org/10.1016/j.eururo.2022.09.030.

Article  CAS  PubMed  Google Scholar 

Nakauma-González JA, Rijnders M, van Riet J, et al. Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma. Eur Urol. 2022;81(4):331–6. https://doi.org/10.1016/j.eururo.2022.01.026.

Article  CAS  PubMed  Google Scholar 

Fong MHY, Feng M, McConkey DJ, Choi W. Update on bladder cancer molecular subtypes. Transl Androl Urol. 2020;9(6):2881–9. https://doi.org/10.21037/tau-2019-mibc-12.

Article  PubMed  PubMed Central  Google Scholar 

Queipo FJ, Unamunzaga GM, Negro BF, et al. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice. Virchows Arch. 2022;481(2):191–200. https://doi.org/10.1007/s00428-022-03361-0.

Article  CAS  PubMed  Google Scholar 

Grivas P, Bismar TA, Alva AS, et al. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol. 2020;38(4):262–8. https://doi.org/10.1016/j.urolonc.2019.11.004.

Article  CAS  PubMed  Google Scholar 

Szarvas T, Jardin-Watelet B, Bourgoin N, et al. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect. 2019;8(5):625–33. https://doi.org/10.1530/EC-19-0068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen P, Jing Y, Zhang R, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018;37(22):3039–44. https://doi.org/10.1038/s41388-018-0192-5.

Article  CAS  PubMed  Google Scholar 

Goyal S, Banga P, Meena N, et al. Prognostic significance of tumour budding, tumour-stroma ratio and desmoplastic stromal reaction in gall bladder carcinoma. J Clin Pathol. 2023;76(5):308–14. https://doi.org/10.1136/jclinpath-2021-207957.

Article  PubMed  Google Scholar 

Hu K, Miao L, Goodwin TJ, et al. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano. 2017;11(5):4916–25. https://doi.org/10.1021/acsnano.7b01522.

Article  CAS  PubMed